GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (STU:R9Q) » Definitions » Debt-to-Revenue

Recce Pharmaceuticals (STU:R9Q) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Recce Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Recce Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.15 Mil. Recce Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.32 Mil. Recce Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2024 was €0.00 Mil.


Recce Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Recce Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Debt-to-Revenue Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only N/A N/A N/A N/A N/A

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Recce Pharmaceuticals's Debt-to-Revenue

For the Biotechnology subindustry, Recce Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recce Pharmaceuticals's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's Debt-to-Revenue falls into.


;
;

Recce Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Recce Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.138 + 0.362) / N/A
=N/A

Recce Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.149 + 0.322) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


Recce Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Recce Pharmaceuticals Business Description

Traded in Other Exchanges
Address
180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.

Recce Pharmaceuticals Headlines

No Headlines